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Appendix 1. UKFOCSS Phase 2 Inclusion and Exclusion Criteria 
Eligibility is determined as follows: 
 
The volunteer must be aged at least 35 years and should either have been affected by one of 
the following cancers or be a first degree relative (FDR) of an affected family member 
NB Tubal & primary peritoneal cancers may be considered equivalent to ovarian cancers 
Families with ovarian or ovarian & breast cancer 
1) ≥2 individuals with ovarian cancer who are FDR 
2) One ovarian cancer and 1 breast cancer <50 years who are FDR 
3) One ovarian cancer and 2 breast cancers < 60 years who are FDR 
4) Breast cancer in volunteer/ proband (≤45 years) and mother with both breast and ovarian cancer 
(in the same person)  
5) Breast cancer in volunteer/ proband (≤40 years) and sister with both breast and ovarian cancer (in 
the same person) 
6) Criteria 1, 2, and 3 can be modified where paternal transmission is occurring i.e. families where 
affected relatives are related by second degree through an unaffected intervening male relative 
and there is an affected sister are eligible. 
Families with a known gene mutation 
7) The family contains an affected individual with a mutation of one of the known OC predisposing 
genes e.g. BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS1 and PMS2. 
Families with colorectal cancer (HNPCC or Lynch syndrome) 
8) The family contains ≥3 individuals with a HNPCC related cancer#, who are FDR and  ≥1 case is 
diagnosed before 50 years and the cancers affect ≥1 generation 
#HNPCC related cancers - colorectal, endometrial, small bowel, ureteric and renal pelvic cancers 
Families with only breast cancer* 
9) ≥4 breast cancers 
10) 3 breast cancers related by FDR  
a) one ≤30 years or 
b) all ≤40 years or 
c) one MBC (Male Breast Cancer) and one bilateral breast cancer 
11) Breast cancer in volunteer/ proband (≤50 years) and  
a) breast cancer in mother (age of onset being ≤30 years in one and ≤50 years in the other) or 
b) bilateral breast cancer in mother (≤40 years onset) or 
c) one MBC and one bilateral breast cancer 
12) Two MBC (one <40 years) in the family and proband is a FDR of one of them 
 
Families with Ashkenazi Jewish ethnicity (additional criteria)* 
AJ ethnicity and any one of the following: 
13) Breast cancer (<40 years) or bilateral breast cancer (first cancer <50 years) in volunteer/ proband, 
irrespective of FH (family history) of cancer 
14) Breast cancer in volunteer/ proband (<50 years) and one FDR with breast cancer (<50years) or 
ovarian cancer (any age) or MBC (any age) 
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15) Breast cancer in volunteer/ proband (<60 years) and one FDR with breast cancer (<40 years) or 
ovarian cancer (any age) or MBC (any age) 
16) One FDR with ovarian cancer (<50 years) 
17) FDR with breast and ovarian cancer in the same woman (any age) 
18) Two FDR with breast cancer (<40 years) 
19) Two MBC (<60 years) in the family and proband is a FDR of one of them 
 
*Families in these categories negative on full BRCA1 and BRCA2 screening are ineligible   
 
Exclusion Criteria 
1) Past history of bilateral oophorectomy (women with one or both fallopian tubes still        present 
are eligible) 
2) Age <35 years 
3) Women participating in other ovarian cancer research trials  
4) Women who have tested negative for a pathological mutation found in an affected family 
member. Similarly, those who obtain a negative result after recruitment need to be withdrawn.  
5) Breast cancer-only families (inclusion criteria 9-12) and Ashkenazi families (criteria 13-19) 
are not eligible if full gene mutation screening has been done and no mutation found (such 
families are not thought to be at increased risk of developing ovarian cancer).  
6) Women should not be recruited if risk reducing salpingo-oophorectomy (RRSO) is imminent, 
but those with an intention to have RRSO at some (unspecified) date in the future are eligible. 
Good clinical practice dictates that even if a woman is not recruited to UK FOCSS, she should 
have a transvaginal ultrasound and CA125 performed shortly before RRSO to reduce the risk 
that an occult cancer only comes to light at the time of surgery. 
 
Definition of ‘Ovarian Cancer’  
For the purposes of determining a woman’s eligibility based on the occurrence of ovarian cancer in 
her family history, the term ‘ovarian cancer’ specifically refers to ‘epithelial ovarian cancer’ and does 
not include ‘borderline ovarian tumour’. 
 
 
Appendix 2. UKFOCSS Phase 2 menopause algorithm 
 
Menopause algorithm questions: 
 
A. Is it more than 12 months since you have had a period? 
B. Have you had a hysterectomy (an operation to remove your womb)? 
C. Are you taking hormone replacement therapy? 
D. Have you ever had hot flushes and/or night sweats for more than 1 month? 
E. Age = Equal to or greater than 56 years old? (The database automatically calculates the 
response to this question.) 
 
The study database classifies women as premenopausal or postmenopausal according to their 
responses to these questions (see Table A2 below). 
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Question 
 
A B C D E Classification 
INTACT UTERUS 
No HRT 
Y N N A A Postmenopausal 
N N N A A Premenopausal 
HRT 
A N Y Y A Postmenopausal 
A N Y N Y Postmenopausal 
A N Y N N Premenopausal 
HYSTERECTOMY 
HOT 
FLUSHES 
A Y A Y A Postmenopausal 
NO HOT 
FLUSHES 
A Y A N Y Postmenopausal 
A Y A N N Premenopausal 
 
Table A2. Menopause algorithm calculator 
 
Y = Yes, N = No, A = not applicable (answer does not contribute to classification) 
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Appendix 3. Protocol following ROCA/scan results 
 
The first ROC value triaged women to; (i) 4-monthly routine screening (‘normal’; <85th percentile 
ROC), (ii) TVS within two months and repeat CA125 measurement after two months (‘intermediate’; 
85th percentile ROC up to 1 in 5 ROC) or (iii) referral for clinical assessment by collaborating centre 
gynaecologist (‘elevated’; >1 in 5 ROC). Subsequent TVS and ROC results triggered; (i) return to 
routine screening, (ii) repeat CA125, (iii) repeat CA125 and TVS, (iv) referral, or (v) triage by CC study 
clinician (ANR, RM, RH) if ROC was persistently intermediate or TVS unsatisfactory. If ROC remained 
‘normal’, TVS was requested annually. The triage protocol is summarised in the figure below. 
 
In addition to this protocol, CA125 was repeated at CC clinicians’ discretion within 2 months if the 
ROC was ‘normal’ but CA125 had increased by >50% since the prior test. Woman referred but not 
undergoing surgery were, at CC clinicians’ discretion, transferred to ‘high-alert screening’, comprising 
repeat TVS and CA125 at 2, 6 and 10 months. 
 
In 2010 the trial steering committee modified the protocol (implemented 13/05/2010) because some 
centres could not provide timely scans: the ‘intermediate’ category was split into ‘low intermediate’ 
(85th-92·5th percentile ROC) and ‘high intermediate’ (>92·5th percentile ROC up to 20% ROC), 
respectively triggering repeat CA125 within 2 months, and repeat CA125 and TVS within 2 months.  
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Figure A3. Risk of Ovarian Cancer Algorithm (ROCA) triage protocol 
The figure should be read from left to right  
 
Results Classification:  
ROC: N = Normal; I = Intermediate*; E = Elevated  
Scans: N = Normal; U = Unsatisfactory; A = Abnormal 
 
Action:  
RS = Routine Screening (i.e. 4-monthly CA125 and annual scan) 
CD = Clinical Decision  
Refer = Referral for clinical assessment by local study centre gynaecologist  
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“Clinical Decision” = management at discretion of study clinicians at co-ordinating centre. Clinical 
decisions will be to (i) refer the woman to a gynaecologist for further investigation, (ii) return to routine 
screening or (iii) undergo repeat CA125 and or ultrasound sooner than routine screening. 
 
*from 13/05/10 Intermediate results were sub-classified into High Intermediate and Low Intermediate. 
Actions following these results were as follow: 
High Intermediate – scan within 2 months and repeat CA125 after 2 months 
Low Intermediate – repeat CA125 after 2 months 
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Appendix 4. UKFOCSS Ultrasound scan results proforma 
 
 FAMILIAL OVARIAN CANCER SCREENING RESULTS  
 
FIRST NAME   _____________________________   SURNAME  ___________________________________ 
 
DATE OF BIRTH   _____/_____/_____   STUDY ID  ___________________________________ 
PELVIC ULTRASOUND RESULTS 
Hospital   ______________________________________ DATE OF SCAN    _____/_____/_____  
Department   ULTRASOUND  GYNAECOLOGY  OTHER _______________________ 
Grade of scanner  ULTRASONOGRAPHER  RADIOLOGIST  GYNAECOLOGIST  OTHER 
Scan performed by       _____________________________(Please print) 
Date of last period   ____/_____/_____            
Mode of scan   TRANSABDOMINAL   TRANSVAGINAL  BOTH 
Using hormones  YES      NO 
Reason hormone use   CONTRACEPTION    HRT    TREATMENT     OTHER   
Details of hormone use _________________________________________________________________________________ 
Oophorectomy     LEFT OOPHORECTOMY      RIGHT OOPHORECTOMY  
  Hysterectomy 
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DETAILS OF OVARIAN SCAN 
                                   
 LEFT OVARY RIGHT OVARY 
 
Visualisation 
   SEEN 
   NOT SEEN / GOOD VIEW  
   NOT SEEN / POOR VIEW 
   NOT SEEN / PREVIOUS 
OOPHERECTOMY 
   SEEN 
   NOT SEEN / GOOD VIEW 
   NOT SEEN / POOR VIEW 
   NOT SEEN/ PREVIOUS 
OOPHERECTOMY 
 
Reason not seen 
    BOWEL              FIBROIDS 
    PELVIC VARICOSITIES 
    OTHER 
    BOWEL              FIBROIDS 
    PELVIC VARICOSITIES 
    OTHER 
Ovarian 
dimensions 
             mm               mm                mm              mm               mm                mm 
Morphology 
  
   NORMAL  SUGGESTIVE OF PCO 
   SINGLE OR MULTIPLE SIMPLE CYSTS 
   ALL OTHER MORPOLOGY 
   NORMAL  SUGGESTIVE OF PCO 
   SINGLE OR MULTIPLE SIMPLE CYSTS 
   ALL OTHER MORPOLOGY 
Description  
ovarian 
morphology 
  
Max double endometrial thickness _______ mms  Ascites   YES      NO  
Details of any other pelvic abnormality noted 
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DETAILS OF ANY OVARIAN LESION DETECTED  
 
LEFT OVARY RIGHT OVARY 
Cyst dimensions 
   mm                           mm                      mm    mm                           mm                      mm 
Cyst wall thickness mm mm 
Cyst wall structure  Smooth              Irregular  Smooth          Irregular 
Fluid in cyst Anechoic            Random 
Echogenicity 
Uniform Echogenicity 
Anechoic        Random Echogenicity 
Uniform Echogenicity 
Cyst structures 
Septae                 Papillations Septae             Papillations 
Maximum septa thickness                                mm                             mm 
Size of largest papillation 
                               mm                             mm 
Solid areas 
 Yes                      No  Yes                 No 
Overall impression of lesion  
 
(Classification using International 
Ovarian Tumour Analysis criteria) 
 
 
 
 
 
 
 
 
 
 
Any other details of abnormal 
area 
  
 
DOPPLER STUDY OF ABNORMAL AREA  
 
Doppler performed 
 YES                      NO  YES                      NO 
Presence of colour signal  
 YES                      NO  YES                      NO 
Location of colour signal 
 SEPTAE          WALL  SOLID 
AREA             PAPILLATIONS                  
 OTHER 
 SEPTAE     WALL    SOLID 
AREA             PAPILLATIONS                  
 OTHER 
Lowest PI measured 
  
Peak systolic velocity   
 FOLLOW UP PLAN  
 
Unilocular cyst 
Unilocular solid 
Multilocular cyst 
Multilocular solid 
Solid 
Unilocular cyst 
Unilocular solid 
Multilocular cyst 
Multilocular solid 
Solid 
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Report Completed By   ________________________________________________(Please print) 
Date    _____/_____/_____ 
Appendix 5. UKFOCSS Phase 2 ultrasound protocol 
 
Ultrasound 
Transvaginal ultrasonography will be performed at collaborating centres.  All scans will be performed 
by ultrasonographers, gynaecologists or radiologists with particular expertise in transvaginal 
ultrasonography.  
 
Pelvic ultrasound will occur annually. The timing of scans will be determined by the ROCA results. 
These scans will be organised by the local UK FOCSS collaborators. If after 12 months of screening a 
woman has not had a scan prompted by her ROC results, she will have an annual scan performed. 
 
As ovarian appearance varies with different aspects of the ovarian cycle in premenopausal women, 
where possible, scans will be scheduled for the early follicular phase (day 3-6 of the cycle).  Two aspects 
will be assessed: 
Ovarian Size: Ovarian diameter will be measured in 3 dimensions and used to calculate ovarian volume 
using the formula for an ellipsoid (d1 x d2 x d3 x 0.523). 
Ovarian Morphology: Ovarian echogenicity will be assessed for the presence of cysts, cyst septae, solid 
areas and solid papillations.   
 
Morphology will be classified as normal or abnormal as follows: 
 
Normal 
 Uniform ovarian echogenicity or  
 One or both ovaries not visualised despite a good view of the pelvic side wall 
(i.e. iliac vessels visualised) or  
 Polycystic ovaries with classical scan features of small peripheral cysts and 
increased stromal echogenicity, or 
 Simple cysts (i.e. cysts with no septae or papillations and thin wall with regular 
internal outline) < 5 cm in diameter or 60 cc in volume. 
 
Abnormal 
 Single simple cysts > 5 cm in diameter, or 60 cc in volume, or 
 Multiple simple cysts or 
 All complex morphology (non-uniform ovarian echogenicity)  
Examples are shown in Figure 2 overleaf. 
 
 
 
 Examples of Complex Ovarian Morphology 
 
 
 
 
 
Septae  
 
 
 
Walls 
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The overall scan result is classified as Normal (N), Unsatisfactory (U) or Abnormal (A), depending upon 
the following Table: 
 
 
Transvaginal Scan Classification Algorithm 
 
Ovary 1 Ovary 2 Result 
Not visualised, poor view Not visualised, poor view U 
Not visualised, poor view Normal morphology U 
Not visualised, poor view Simple cyst of <60cc or mean diameter 
≤5cms 
U 
Not visualised, poor view Not visualised, good view of iliac vessels U 
Abnormal morphology Normal morphology A 
Abnormal morphology Not visualised, good view of iliac vessels A 
Abnormal morphology Not visualised, poor view A 
Abnormal morphology Simple cyst of any size A 
Simple cyst >60cc or mean diameter 
>5cms 
Normal morphology A 
Simple cyst >60cc or mean diameter 
>5cms 
Not visualised, poor view A 
Simple cyst >60cc or mean diameter 
>5cms 
Simple cyst >60cc or mean diameter 
>5cms 
A 
Simple cyst >60cc or mean diameter 
>5cms 
Not visualised, good view of iliac vessels A 
Ascites or fluid in POD >10mms, irrespective of ovarian findings  A 
Normal morphology Normal morphology N 
Normal morphology Simple cyst of <60cc or mean diameter ≤ 
5cms 
N 
Normal morphology Not visualised, good view of iliac vessels N 
Not visualised, good view of iliac vessels Not visualised, good view of iliac vessels  N 
POD = Pouch of Douglas, N = Normal, U = Unsatisfactory, A = Abnormal. 
 
Blood flow: Colour Doppler measurements (presence of a signal, site) are recorded in cases where a 
simple cyst or complex ovarian morphology is detected. 
Fallopian Tube Morphology: This will be recorded as Normal or Abnormal for each tube. Abnormal 
morphology will result in the volunteer being placed on “Clinical Decision”, unless the overall 
classification of the scan (using the ovarian morphology criteria in Table 2 above) is Abnormal, in which 
case the volunteer will be referred to her named rapid access gynaecologist for assessment. 
 
The management of women according to scan results is described in Appendix 3. 
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Appendix 6. Protocol for risk-reducing surgery in UKFOCSS Phase 2 
Background 
All women on UK FOCSS are aged over 35 years and are estimated to be at >10% lifetime risk of 
developing ovarian/ fallopian tube or primary peritoneal cancer. They should therefore have been 
counselled about the possibility of risk-reducing surgery when they were initially recruited to the study. 
Women on UK FOCSS are entitled to request further advice about prophylactic surgery at any point 
and centres should provide easy access to a gynaecologist who regularly performs laparoscopic risk 
reducing salpingo-oophorectomy (RRSO). Any premenopausal woman opting for surgery should 
receive detailed counselling about the risks and benefits of RRSO in terms of the effect on subsequent 
risk of ovarian/fallopian tube or primary peritoneal cancer. In addition, the effect of RRSO on subsequent 
reduction in breast cancer risk and the consequences of receiving/declining HRT following RRSO 
should also be explained. Irrespective of menopausal status, all women should be counselled about the 
risks of the procedure. These will depend on individual circumstances, such as body mass index, 
previous surgery and medical comorbidity. 
 
Surgical Approach 
Because BRCA-carriers are at increased risk of tubal cancer as well as ovarian cancer, it is mandatory 
to remove the Fallopian tubes. These should be removed as close to their insertion on the uterus as is 
technically feasible. It is therefore recommended that formal excisional techniques (e.g. bipolar 
diathermy and laparoscopic scissors or harmonic scalpel) are used. Microscopic occult cancers occur 
predominantly at the distal end of the tube and have not as yet been reported as occurring in the 
intramural portion of the tube, so removal of intramural portion of the tube is not required. 
 
Peritoneal washing are essential because in the event of an occult ovarian or fallopian tube cancer 
being identified on histology positive washings upstage an apparent stage 1a cancer to a Stage 1c 
cancer, possibly altering management in terms of adjuvant chemotherapy. Positive washings have also 
been reported in the absence of occult ovarian or tubal cancers raising the possibility of an occult 
primary peritoneal cancer. 
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A thorough inspection of the entire pelvic and abdominal cavity is mandatory to exclude the presence 
of peritoneal cancer. This should include the upper abdomen, paying particular attention to the liver, 
diaphragmatic surfaces and the omentum. Any suspicious area should be biopsied. Surgical specimens 
should be removed in an endobag to avoid seeding occult malignancy into the port sites.  
 
Pathology Protocol 
Meta-analysis of published RRSO series suggests that when a strict histopathological specimen 
sectioning protocol is used, the rate of occult ovarian and tubal cancers increases from 2.5 to 5%. 
Therefore, not only is such a protocol mandatory, but also, women undergoing RRSO should be 
counselled about the possible need for completion staging in the event of an occult cancer being 
detected. 
  
A suggested protocol follows: 
 
Ovaries: 
1. After standard recording of size and macroscopic appearance, each ovary should be serially 
sectioned transversely at 2-3 mm intervals from pole to pole and processed in toto. 
Fallopian tubes: 
1. The overall length, diameter and macroscopic appearance of each fallopian tube should be stated.  
2. Transverse serial sections at 2-3 mm intervals to be taken from the isthmic to the fimbrial end and 
placed in cassettes sequentially, with 2-4 slices per cassette, to include the entire tube and any 
mesosalpinx.  
3. Cassettes should be labelled to indicate isthmic, ampullary and infundibular segments.  
4. An alternative approach suggested to maximise exposure of the fimbrial mucosa is to amputate the 
infundibular segment which is then serially sectioned longitudinally, the remainder of the tube being 
transversely sectioned. 
 
 
Peritoneal/Omental biopsies: 
1. If submitted, these should be processed in their entirety. 
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Peritoneal Washings: 
1. Cytological examination of fluid obtained after instillation of normal saline into the peritoneal cavity. 
 
For any queries about pathological processing, please contact: Dr. Elizabeth Benjamin, Consultant 
Pathologist, Dept of Pathology, University College London Hospital, Rockefeller Building, 21 University 
Street, London WC1E 6JJ. Tel:  020 7679 6045. Email: elizabeth.benjamin@uclh.nhs.uk 
 
Optimum age of RRSO 
The age of onset of ovarian cancer is younger in BRCA1 mutation carriers than in BRCA2 carriers. Our 
current recommendation is that once child-bearing is complete, RRSO is reasonable from 40 years in 
BRCA1 carriers and from 45 years in BRCA2 carriers, with HRT until age 50 years (for women who 
have not had breast cancer). However, the decision is further individualised based on age of diagnosis 
of the youngest women in the family to have ovarian cancer (RRSO is undertaken at least 5 years 
ahead of this age), the patient’s decisions with regard to management of her breast cancer risk, her 
willingness to take HRT until 50 years and other individual views about surgery and oophorectomy. 
 
Need for Hysterectomy 
Hysterectomy is recommended in women on UK FOCSS if they are known to carry a HNPCC mutation 
(such women are at 40%-60% lifetime risk of developing endometrial cancer). Occult endometrial 
cancer has also been demonstrated at hysterectomy in women with HNPCC of Lynch Syndrome (LS). 
Peritoneal washings should be obtained for cytology (as described above) in these women too. All 
women with HNPCC or LS should have endometrial sampling before prophylactic hysterectomy.  
Hysterectomy at the time of RRSO may also be justifiable in some women who are symptomatic from 
benign gynaecological pathology. 
Some of the women on UK FOCSS who have had breast cancer may be on tamoxifen. There is a small 
increased incidence of endometrial cancer in women over 50yr taking tamoxifen (0.3% per annum vs. 
0.06% in women on placebo). These cancers are usually Stage 1. It is not usual to suggest 
hysterectomy based solely on tamoxifen usage, but it does need to be discussed with the patient. It is 
sensible to perform dilation and curettage on all women on tamoxifen undergoing PBSO.  
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Post-surgical management 
1. Women who have not had breast cancer should be prescribed HRT until the age of 50. It is best to 
start this directly after surgery. 
2. The situation for women who have had breast cancer should be discussed in advance of surgery 
with the woman’s breast oncology team. The plan should be documented prior to surgery to avoid 
subsequent confusion. 
 
Documention 
Following RRSO, the Primary Contact should send hard copies of the following to the UK FOCSS 
coordinating centre: 
1. Operation note 
2. Histology report 
3. Cytology report (peritoneal washings) 
4. GP discharge summary (or other documentation of post-operative course) 
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Appendix 7. Surgical complexity scoring on UKFOCSS Phase 2 
Procedure  Points 
TAHBSO  1 
Omentectomy  1 
Pelvic lymphadenectomy  1 
Paraaortic lymphadenectomy  1 
Pelvic peritoneum stripping  1 
Abdominal peritoneum stripping  1 
Large bowel resection  2 
Diaphragm stripping/resection   2 
Splenectomy  2 
Liver resection/s  2 
Small bowel resection/s   2 
Rectosigmoidectomy with anastomosis  3 
Table A7. Surgical complexity scoring from Aletti GD, Dowdy SC, Podratz KC, et 
al. Relationship among surgical complexity, short-term morbidity, and overall survival 
in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 2007; 197: 
676.e1-7. 
 
Key: TAHBSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy 
To calculate total score per patient, simply add scores from individual procedures 
undertaken during surgery and allocate to complexity group as follows:   
Total score 1-3 = low complexity 
Total score 4-7 = intermediate complexity 
Total score >7 = high complexity  
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Appendix 8. Study participant demographics 
 n % 
Pre-menopausal at 
recruitment 
2299 52.9 
Breast cancer prior 
to recruitment 
576 13.2 
Ever used HRT (HQ1) 572 13.2 
Never used HRT 
(HQ1) 
2463 56.6 
Data missing 1313 30.2 
Ever used COCP 
(HQ1) 
1917 44.1 
Never used COCP 
(HQ1) 
  
Data missing (HQ1)   
Ever been pregnant 
<6mths (HQ1) 
1233 28.4 
Ever been pregnant 
>6 mths (HQ1) 
2506 57.6 
Never been pregnant 
(HQ1) 
  
Data missing (HQ1) 609 14.0 
Age at recruitment 45·5 yr (range 34·2 to 84·8) n=3438 
Height (cm) median 
(range) (HQ1) 
 
Weight (kg) median 
(range) (HQ1) 
67.9 (39.4 - 168) n=3248 
Ethnic origin (from HQ2 April 2013 n=2694) 
White 2224 51.1 
Black 28 0.6 
Asian 48 1.1 
Other 18 0.4 
Data missing 2030 46.7 
HQ 1 n= 3325 Jan 2011 
HQ 2 n= 2694 April 2013 
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Appendix 9. Apparent compliance with requested screening tests on 
UKFOCSS Phase 2 
 
Blood test type Tests requested  
n (% of all requests) 
Tests received 
n (% of requested) 
Routine  29,450 (84·0) 27,138 (92·1) 
Repeat after non-normal ROCA and/or scan 4,843 (13·8) 4,716 (97·4) 
Clinical decision  766 (2·2) 733 (95·7) 
Total  35,059 32,587* (92·9) 
 
Scan type Scans requested  
n (% of all requests) 
Results received  
n (% of requested) 
Annual scans 9,619 (76·3) 9,100 (94·6) 
Repeat after non-normal ROCA and/or scan 2,825 (22·4) 2,792 (98·8) 
Repeat after unsatisfactory scan  168 (1·3) 146 (86·9) 
Total  12,612 12,038 (95·4) 
 
Table A8. Apparent compliance with requested screening tests on UKFOCSS Phase 2 
 
* of these 2,233 (6·9% were discarded as they were receive by the lab outside the 56 hour post-
venepuncture time-limit) 
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Appendix 9. UKFOCSS Collaborators, Laboratory Team, Data Monitoring 
Committee, Trial Steering Committee, Outcomes Committee members 
Centre Collaborators 
Belfast Patrick Morrison, Hans Nagar 
Birmingham James Nevin 
Bristol Robert Anderson, John Murdoch 
Cambridge Robin Crawford 
Cardiff Jonathon Gray, Mark Rogers 
Cheltenham & 
Gloucester 
Robert Gornall 
Chester Sharon Rowe 
Cumberland Sheila Pearson 
Derby  Ian Scott, Howard Jenkins 
Durham Partha Sengupta 
Dundee David Goudie  
East  Kent Andy Nordin 
Edinburgh Mary Porteous 
Gateshead Richard Edmondson 
Glasgow Rosemary Davidson 
Guys Gabriella Pichert, Chris Jacobs 
Hammersmith Sadaf Ghaem-Maghami 
Hull Mike Lind, David Poole 
Kettering Robert Haughney 
Leeds Carol Chu, Roger Rand, Richard Hutson, Ian Beck, Cheng Choy 
Leicester Richard Trembath, Quentin Davies 
Lincoln Martin Lamb 
Liverpool Carol Bejamin 
London Northwest Huw Dorkins 
London UCLH Usha Menon, Michelle Johnson 
Manchester Gareth Evans 
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Mid Essex Colin Partington, Christopher Goodfellow 
Milton Keynes Christopher B-Lynch 
Newcastle Fiona Douglas 
North England Paul Brennan, Mary George, John McDonald 
North 
Staffordshire 
Vijay Menon 
North Wales Alex Murray, Philip Banfield, Simon Leeson, Philip Toon 
Northampton Sue Price, Alistair Duncan 
Nottingham Susan Ritchie, Karin Williamson 
Oxford Cyril Chapman, Anneke Lucassen, Lucy Side, Lisa Walker 
Peninsula Carole Brewer, Tony Falconer, Tito Lopes 
Sheffield Jackie Cook 
Somerset West Robert Fox 
Southampton Diana Eccles 
St. George's 
London 
Shirley Hodgson 
Surrey Gareth Beynon 
Swansea Alex Murray, Omar Freites  
The Royal 
Marsden, London 
Rosalind Eeles 
Wycombe/Stoke Damien Eustace 
West Kent Andreas Papadopoulos 
Co-ordinating 
Centre lab 
Jeremy Ford, Richard Gunu 
Data Monitoring 
Committee 
Shehla Mohammed, Mahesh Parmar (chair), Karina Reynolds 
Trail Steering 
Committee 
Louise Bayne (lay member), Kate Brain, Derek Cruikshank, Stephen 
Duffy, Diana Eccles, Lindsay Fraser, Ian Jacobs, Usha Menon, 
Julietta Patnick (chair), Adam Rosenthal, Steve Skates 
Outcomes 
Committee 
Elizabeth Benjamin, Adam Rosenthal, Naveena Singh 
 
Table A9. UKFOCSS Collaborators, Laboratory Team, Data Monitoring Committee, Trial Steering 
Committee, Outcomes Committee members 
